NeilJKormanMD

PubMed

• Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Labe...
  Richard B Warren, Lev Pavlovsky, Antonio Costanzo, Michael Bukhalo, Neil J Korman
  Dermatology and Therapy. 2025-01-17
• The association between obesity and efficacy of psoriasis therapies: An expert consensus panel.
  Joshua Burshtein, April Armstrong, May Chow, Lauren DeBusk, Brad Glick
  Journal of the American Academy of Dermatology. 2024-12-19
• Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Ar...
  Richard B Warren, Lev Pavlovsky, Antonio Costanzo, Michael Bukhalo, Neil J Korman
  Dermatology and Therapy. 2024-12-01

Journal Articles

• Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study throu...  
  Langley RG, Lebwohl M, Krueger GG, Szapary PO, Wasfi Y, Chan D, Hsu MC, You Y, Poulin Y, Korman NJ, Prinz JC, Reich K, Br J Dermatol, 1/1/2015
• Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts  
  Murrell DF, Marinovic B, Caux F, Prost C, Ahmed R, Wozniak K, Amagai M, Bauer J, Beissert S, Borradori L, Culton D, Fairley JA, Fivenson D, Jonkman MF, Marinkovich MP,..., J Am Acad Dermatol, 1/1/2015
• Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis: 52-week results of a phase 3, randomised, controlled trial (ES...  
  Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RGB, Hu CC, Stevens RM, Day RM, Gordon KB, Korman NJ, Griffiths CEM, J Am Acad Dermatol, 1/1/2015
• Clinical symptoms and self-reported disease severity among patients with psoriasis - Implications for psoriasis management  
  Korman NJ, Zhao Y, Li Y, Liao M, Tran MH, J Dermatolog Treat, 1/1/2015
• Quantifying Harmful Effects of Psoriatic Diseases on Quality of Life: Cardio-metabolic outcomes in psoriatic arthritis study  
  Dalal DS, Lin YC, Brennan D, Borkar N, Korman NJ, Husni ME, Semin Arth Rheum, 1/1/2015
• Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biol...  
  Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM, Gottlieb AB and 64 collaborating investigators (Korman NJ), Ann Rheum Dis, 1/1/2014
• In response to “Relationship between metabolic syndrome and carotid intima-media thickness: cross-sectional comparison between psoriasis and psoriatic arthritis  
  Lin YC, Dalal D, Brennan DM, Kim ES, Husni ME, Churton S, Korman NJ, Arthritis Care Res (Hoboken), 1/1/2014
• Relationship between metabolic syndrome and carotid intima-media thickness: cross-sectional comparison between psoriasis and psoriatic arthritis  
  Lin YC, Dalal D, Churton S, Brennan DM, Korman NJ, Kim ES, Husni ME, Arthritis Care Res (Hoboken), 1/1/2014
• Psoriasis as a systemic disease  
  Grozdev I, Korman NJ, Tsankov N, Clin Dermatol, 1/1/2014
• Systemic Treatment of Psoriasis May Reduce the Risk of Heart Disease  
  Churton S, Brown L, Shin T, Korman NJ, Drugs, 1/1/2014
• Research Gaps in Psoriasis: Opportunities for Future Studies  
  Ryan C, Korman NJ, Gelfand JM, Lim HW, Elmets CA, Feldman SR, Gottlieb AB, Koo JYM, Lebwohl MJ, Leonardi CJ, Van Voorhees AS, Bhushan R, Menter A, J Am Acad Dermatol, 1/1/2014
• Psoriasis and cardiovascular risk factors: Increased serum myeloperoxidase and corresponding immunocellular overexpression by CD11b+ CD68+ macrophages in skin lesions  
  Cao L, Soler DS, Grozdev I, Rodriguez ME, Babineau DC, Feig RL, Carman TL, Gilkeson RC, Orringer CE, Kern EF, McCormick TS, Cooper KD, Korman NJ, Am J Transl Res, 1/1/2013
• Molecular analysis of dermatophytes suggests spread of infection among household members  
  Ghannoum MA, Mukherjee PK, Warshaw E, Korman NJ, Tavakkol A, Cutis, 1/1/2013
• Co-morbidities of Psoriasis  
  Churton S, Doud K, Korman NJ, Exp Rev Dermatol, 1/1/2013
• Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States  
  Mercy K, Kwasny M, Cordoro KM, Menter A, Tom WL, Korman NJ, Belazarian L, Armstrong AW, Levy ML, Paller AS, Ped Dermatol, 1/1/2013
• Paving the Way for Future Medical Dermatology Leaders in Psoriasis and Psoriatic Arthritis: 1st Annual Mentoring Program for Dermatology Fellows  
  Husni ME, Duch D, Korman NJ, Psoriasis Forum, 1/1/2013
• A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1  
  Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ et al, Dermatol Ther (Heidelb), 1/1/2012
• Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2  
  Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, et al, Dermatol Ther (Heidelb), 1/1/2012
• Treatment of Refractory Prurigo Nodularis with Lenalidomide  
  Kanavy H, Bahner J, Korman NJ, Arch Dermatol, 1/1/2012
• Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation  
  Bae YS, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl, MJ, Young M, Bebo B, Kimball AB for the National Psoriasis Foundation, J Am Acad Dermatol, 1/1/2012
• Treatment of pustular psoriasis: From the Medical Board of the National Psoriasis Foundation  
  Robinson A, VanVoorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF, and Kalb RE, J Am Acad Dermatol, 1/1/2012
• The compact SF-12 can detect both physical and mental impacts of psoriasis severity  
  Grozdev I, Kast D, Cao L, Carlson D, Kavlick K, Feig R, Pujari P, Schmotzer B, Babineau D, Kern E, McCormick T, Cooper K, Korman NJ, J Invest Dermatol, 1/1/2012
• Langerhans Cell Histiocytosis: Case Report & Review of the Literature  
  Park L, Korman NJ, Journal Cut Med Surg, 1/1/2012
• Diagnosis and Treatment of Pemphigus Vulgaris  
  Kittridge A, Al-Dabagh A, Korman NJ, Treatment Strategies – Dermatology, 1/1/2012
• In response to "Treatment of psoriasis with cyclosporine in patients with hepatitis C infection: Risk or opportunity”  
  Frankel A, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl M, Bebo BF Jr, Gottlieb A, J Am Acad Dermatol, 1/1/2011
• Join now to see all

Books/Book Chapters

• Blistering Diseases 
  Chapter: Pemphigus vulgaris. 
  Page 383 - 388Kim J, Hertl M, Korman NJ, Murrell DFEditors: Murrell DF.2015
• UpToDate 
  Chapter: Comorbid disease in psoriasis. 
  Korman NJEditors: Basow DS.UpToDate, Waltham, MA2011
• Challenging Cases in Allergic and Immunologic Diseases of the Skin 
  Chapter: Autoimmune Blistering Diseases of the Skin and Mucous Membranes. 
  Page 303 - 321Patton T, Korman NJEditors: Mahmoudi M.Springer, New York, NY2010
• Treatment of Psoriasis 
  Chapter: Psoriasis and Psoriatic Arthritis: A Clinical Review. 
  Page 23 - 39Brown AB, Korman NJEditors: Weinberg JM.Birkhauser, Boston, MA2008
• Treatment of Psoriasis 
  Chapter: Treatment of Psoriasis Utilizing Biologic and Oral Therapies in Development. 
  Page 159 - 164Robinson MR, Korman NJEditors: Weinberg JM.Birkhauser, Boston, MA2008
• Treatment of Psoriasis 
  Chapter: Treatment of Psoriasis With Traditional Systemic Therapies. 
  Page 103 - 120Prodanovich E, Korman NJEditors: Weinberg JM.Birkhauser, Boston, MA2008
• Cytokine and Anti-Cytokine Therapy in Dermatology. 
  Chapter: Anti-Interleukin-12/23. Chapter 14 
  Page 212 - 241Routhouska SB, Cooper KD, Korman NJEditors: Asadullah K, Volk HD and Sterry W.Transworld Research Network, Kerala, India2006
• Cecil Textbook of Medicine 
  Chapter: Macular, papular, vesiculobullous and pustular diseases. 
  Page 2466 - 2475Korman, NJEditors: Goldman L, Ausiello D.W.B. Saunders Co., Philadelphia, PA2004
• Treatment of Skin Disease: Comprehensive Therapeutic Strategies 
  Chapter: Linear IgA bullous dermatosis and chronic bullous dermatosis of childhood. 
  Page 361 - 364Korman, NJEditors: Lebwohl MG, Heymann WR, Berth-Jones J, Coulson I.Mosby, London2002
• Medical Immunology 
  Chapter: Immune mediated dermatologic diseases. 
  Page 495 - 509Korman, NJEditors: Parslow TG, Stites DP, Terr AI, Imboden JB.McGraw-Hill, New York, NY2001
• Atlas of Bullous Disease 
  Chapter: Cicatricial pemphigoid. 
  Page 63 - 74Korman, NJ, Cooper KDEditors: R.E. Jordon.Churchill Livingstone, New York, NY2000
• Conn’s Current Therapy. 
  Chapter: Bullous diseases. 
  Page 826 - 830Korman, NJEditors: Rakel RE.W.B. Saunders Co., Philadelphia, PA2000
• Dermatology: Cutaneous Medicine and Surgery in Primary Care. 
  Chapter: Bullous pemphigoid and other immunologically mediated blistering diseases. 
  Page 233 - 241Korman, NJEditors: Arndt KA, LeBoit PE, Robinson JK, and Wintroub BU.WB Saunders Co., Philadelphia, PA1997
• Basic and Clinical Immunology. 
  Chapter: Immune mediated dermatologic diseases. 
  Page 567 - 578Korman, NJ, Goldstein SM, Wintroub BUEditors: Stites R, Terr AI.Appleton & Lange, Philadelphia, PA1997
• Conn’s Current Therapy. 
  Chapter: Skin diseases of pregnancy. 
  Page 813 - 815Korman NJEditors: Rakel RE.W.B. Saunders Co., Philadelphia, PA1996
• Cutaneous Medicine and Surgery: An Integrated Program in Dermatology. 
  Chapter: Bullous pemphigoid. 
  Page 664 - 673Korman NJEditors: Arndt KA, LeBoit PE, Robinson JK, and Wintroub BU.W.B. Saunders Co., Philadelphia, PA1995
• Current Opinion in Dermatology. 
  Chapter: Laboratory methods in the diagnosis of autoimmune blistering diseases. 
  Page 16 - 20Korman NJEditors: MV Dahl, PJ Lynch.Current Science, Philadelphia, PA1994
• Bullous Diseases. 
  Chapter: Bullous pemphigoid 
  Page 25 - 51Korman NJEditors: J.D. Fine.Igaku-Shoin, New York, NY1992
• Join now to see all

Abstracts/Posters

• Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K _/_ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma
  Neil Korman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Myeloid biomarkers and vascular PET-MRI during psoriasis treatments: preliminary report.
  Golden JB, Santilli S, Muakkassa F, Prabhakar R, O'Donnell JK, Groft S, Galimberti F, Soler DC, McCormick TS, Korman NJ, Cooper KD, J Invest Dermatol, 1/1/2015
• Autosomal Dominant Transgradient Palmoplantar Keratoderma (PPK) and Hypotrichosis Treated Adequately with 13-Cis Retinoic Acid and Acitretin: a novel kindred and reass...
  Cohn HI, Korman NJ, J Invest Dermatol, 1/1/2015
• Does nutrition affect the severity of psoriasis?
  Churton SE, Debanne S, McCormick TS, Cooper KD, Korman NJ, J Invest Dermatol, 1/1/2015
• A phase 1b study in cutaneous T-cell lymphoma (CTCL) with the novel topically applied skin-restricted histone deacteylase inhibitor (HDAC-i) SHP-141.
  Kim YH, Krathen M, Duvic M, Wong H, Porcu P, Tacastacas J, Korman NJ, et al, J Clin Oncol, 1/1/2014
• Phase 3 study of anti-CCR4 monoclonal antibody mogamulizumab vs vorinostat in relapsed or refractory cutaneous t-cell lymphoma.
  Kim YH, Bagot M, Eradat HA, Carson KR, Greer JP, Lansigan F, Zinzani PL, Grandinetti LM, Porcu P, Shustov AR, Korman NJ et al, J Clin Oncol, 1/1/2014
• Physical activity and diet affect systemic inflammation and severity of psoriasis.
  Churton SE, Shin TM, Stocking CM, Debanne S, McCormick TS, Cooper KD, Korman NJ, J Invest Dermatol, 1/1/2013
• Pilot study of cardiovascular event risk biomarkers in psoriasis patients treated with ustekinumab.
  Churton SE, McCormick TS, Cooper KD, Korman NJ, J Invest Dermatol, 1/1/2012
• A cross-sectional study of resistin in psoriasis patients.
  Kast D, Borkar N, Grozdev I, Carlson D, Cao L, Feig R, Pujari P, Babineau D, Kern E, McCormick TS, Cooper KD, Korman NJ, J Invest Dermatol, 1/1/2011
• Psoriasis family history portends earlier age of onset, higher incidence of psoriatic arthritis, and increased likelihood of biologic treatment in psoriasis patients.
  Borkar N, Kast D, Grozdev I, Carlson D, Cao L, Feig R, Pujari P, Schmotzer B, Babineau D, McCormick T, Cooper KD, Korman NJ, J Invest Dermatol, 1/1/2011
• The compact SF-12 can detect both physical and mental impact of psoriasis severity.
  Grozdev I, Kast D, Cao L, Carlson D, Kavlick K, Feig R, Pujari P, Schmotzer B, Babineau D, Kern E, McCormick T, Cooper K, Korman NJ, J Invest Dermatol, 1/1/2010
• Visualization of untreated premature atherosclerosis in a US psoriasis cohort.
  Kast D, Grozdev I, Cao L, Carlson D, Feig R, Pujari P, Babineau D, Kern E, Orringer C, McCormick T, Cooper K, Korman NJ, J Invest Dermatol, 1/1/2010
• Myeloperoxidase as a marker to assess the propensity of psoriasis patients to develop cardiovascular disease in relation to systemic inflammation, lipids and disease s...
  Rodriguez ME, Ohtola J, Sugiyama H, Cao L, Kast D, Babineau DC, Cooper KD, McCormick TS, Korman NJ, J Invest Dermatol, 1/1/2010
• Psoriatic patient cardiovascular event surrogates in relation to markers of systemic inflammation, lipids and disease severity.
  Cao LY, Grozdev I, Feig RL, Carman TL, Babineau DC, Kern EF, Bohaty BR, McCormick TS, Cooper KD, Korman NJ, J Invest Dermatol, 1/1/2009
• Development and reliability of a comprehensive questionnaire on the risk factors, epidemiology and co-morbidities of psoriasis.
  Yang MF, Diaz M, Husni ME, Cooper KD, Korman NJ, J Invest Dermatol, 1/1/2008
• Establishing an interface between a multi-disciplinary psoriasis center and community-based participatory research in psoriasis: A new paradigm.
  Yang MF, Delnay N, McCormick TS, Cooper KD, Korman NJ, J Invest Dermatol, 1/1/2008
• Etanercept effect on regulatory and effector T cells in psoriasis patients.
  Masari JV, Goodman WA, Robinson MR, Routhouska SB, Stevens SR, Cooper KD, Korman NJ, J Invest Dermatol, 1/1/2007
• Non-Hodgkin’s lymphoma-associated pemphigus foliaceus and the use of rituximab for treatment.
  Prodanovic E, Korman NJ, J Am Acad Dermatol, 1/1/2007
• An open label study evaluating the safety and efficacy of a 16 week treatment regimen of alefacept in adults with moderate to severe atopic dermatitis.
  Moul DK, Routhouska SB, Korman NJ, J Am Acad Dermatol, 1/1/2007
• Multiple courses of alefacept for the treatment of psoriatic nail disease in patients with chronic plaque psoriasis.
  Korman NJ, Rico MJ, J Am Acad Dermatol, 1/1/2007
• Safety and efficacy results of a clinical study of efalizumab in patients with alopecia areata.
  Price V, Hordinsky MK, Leonardi C, Roberts J, Olsen E, Rafal E, Korman NJ, Leung H, Garovoy M, Caro I, Whiting D, J Invest Dermatol, 1/1/2006
• Mortality rate of bullous pemphigoid: An evaluation of 223 patients in the United States.
  Pennie ML, Parker SRS, Dyson SW, and Korman NJ, J Am Acad Dermatol, 1/1/2006
• The safety and efficacy of alefacept dose escalation in patients with moderate to severe plaque psoriasis: Results of an open-label study of alefacept 15 mg for 6 wee...
  Moul DK and Korman NJ, J Am Acad Dermatol, 1/1/2006
• The efficacy and safety of alefacept in combination with UVB light or systemic retinoids.
  Korman NJ, Koo JYM, van de Kerkhof P, and Bagel J, J Am Acad Dermatol, 1/1/2006
• Effect of Pimecrolimus (Elidel 1%) Vs Triamcinolone (0.1%) cream on the Inflammatory Cytokines in Atopic Dermatitis.
  Daoud S, Korman NJ, J Invest Dermatol, 1/1/2005
• Join now to see all

Lectures

• Autoimmune Blistering Diseases: What's New 
  American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/1/2019
• Introduction to Clinical Dermatology 
  Case Western Reserve University School of Medicine - 1/1/2015
• Advanced Systemic Therapies 
  Colorado Springs, CO - 1/1/2015
• Autoimmune Blistering Diseases - Approach to Diagnosis and Management 
  Colorado Springs, CO - 1/1/2015
• Basic Immunology - The Acquired Immune System 
  Colorado Springs, CO - 1/1/2015
• Models of Collaborative Practice Between Dermatologists and Dermatology Nurse Practitioners 
  Colorado Springs, CO - 1/1/2015
• Autoimmune Blistering Diseases - Diagnosis and Management 
  Maui, HI - 1/1/2015
• Outside of the Box - Unusual Treatments in Medical Dermatology 
  Maui, HI - 1/1/2015
• Introduction to Clinical Trials: What is the Risk vs the Benefit? 
  New York, NY - 1/1/2015
• New and Emerging Treatments in Pemphigus and Bullous Pemphigoid 
  New York, NY - 1/1/2015
• Immunopathogenesis of Psoriasis and the Role of Biologic Response Modifiers 
  Orlando, FL - 1/1/2015
• Psoriasis: Current and Future Treatments 
  Orlando, FL - 1/1/2015
• Psoriasis Comorbidities – What Do We Know 
  San Francisco, CA - 1/1/2015
• Psoriasis and Psoriatic Arthritis: Existing and Future Treatments 
  University Hospitals Case Medical Center, Cleveland, OH - 1/1/2015
• Dermatology Clinic and in the Inpatient Hospital Service 
  University Hospitals of Cleveland - 1/1/2015
• Pathophysiology, Diagnosis and Management of Immunobullous Diseases and Psoriasis 
  University Hospitals of Cleveland - 1/1/2015
• Use of Immunofluorescence Microsopy for the Diagnosis of Immunobullous Diseases 
  University Hospitals of Cleveland - 1/1/2015
• Understanding Psoriasis Pathogenesis Has Informed The Development Of Agents To Treat Psoriasis 
  Albert Einstein Medical Center, Bronx, NY - 1/1/2014
• Autoimmune Blistering Diseases: Diagnosis and Therapeutic Approach 
  Boston, MA - 1/1/2014
• Psoriasis: Approach to the Patient with Moderate to Severe Disease 
  Boston, MA - 1/1/2014
• What's New in in Systemic and Biologic Treatments for Psoriasis? 
  Columbus, OH - 1/1/2014
• Biologic Therapies for the Treatment of Psoriasis 
  Denver, CO - 1/1/2014
• Research Gaps In Psoriasis Subpopulations 
  Denver, CO - 1/1/2014
• The Evolving Understanding of Psoriasis: From Science to Patient Care 
  Denver, CO - 1/1/2014
• What's New in the Diagnosis & Treatment of Autoimmune Blistering Diseases? 
  Denver, CO - 1/1/2014
• Join now to see all